natgillin/translations-raw huggingface dataset:
In patients who develop HBV reactivation, Idacio should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.
Pri bolnikih, ki se jim pojavi reaktivacija HBV, je treba uporabo zdravila Idacio prekiniti in uvesti učinkovito protivirusno terapijo z ustreznim podpornim zdravljenjem.
Week 26 Week 52 1 p value for Standard Dose versus Low Dose comparison.
26. teden 52. teden 1p vrednost za primerjavo standardnega odmerka proti majhnemu odmerku.
urticaria, bruising (including purpura), dermatitis (including eczema), onychoclasis, hyperhidrosis, alopecia1),
urtikarija, modrice (vključno s purpuro), dermatitis (vključno z ekcemom), oniholiza, čezmerno znojenje, alopecija1),
Table 6 Undesirable effects
Preglednica 6 Neželeni učinki
INFORMATION IN BRAILLE Idacio 40 mg
PODATKI V BRAILLOVI PISAVI Idacio 40 mg
If an anaphylactic reaction or other serious allergic reaction occurs, administration of Idacio should be discontinued immediately and appropriate therapy initiated.
Če se pojavi anafilaktična reakcija ali kakšna druga resna alergijska reakcija, je treba uporabo zdravila Idacio nemudoma prekiniti in uvesti ustrezno zdravljenje.
If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Idacio and is positive for antibodies against double-stranded DNA, further treatment with Idacio should not be given (see section 4.8).
Če se bolniku po zdravljenju z zdravilom Idacio pojavijo simptomi, ki nakazujejo lupusu podobni sindrom, in ima pozitivna protitelesa proti dvojnoverižni DNA, zdravljenja z zdravilom Idacio ne sme nadaljevati (glejte poglavje 4.8).
• any issue you had
• kakršnihkoli težavah,
Note : images for illustration purposes only
Opomba: Slike so namenjene zgolj slikovni ponazoritvi
Figure B 1.4 Check the expiration date on the side of the box (Figure C).
Slika B 1.4 Preverite rok uporabnosti, ki je odtisnjen na strani škatle (Slika C).
Overall, among the patients who discontinued the study, 18% discontinued due to adverse events, and 8% due to insufficient response to adalimumab treatment.
Na splošno med bolniki, ki so prekinili študijo , jih je 18 % prekinilo študijo zaradi neželenih učinkov in 8 % zaradi nezadostnega odziva na zdravljenje z adalimumabom.
• an alcohol pad (included in the box)
• zloženec, navlažen z alkoholom (priložen v škatli),
6.2 Pinch the skin
6.2 Naredite kožno gubo
Should treatment be interrupted, Idacio may be re-introduced as appropriate.
Če je treba zdravljenje prekiniti, je možno zdravljenje z zdravilom Idacio znova uvesti, kakor je primerno.
• Do not use the Idacio pre-filled syringe if it has been dropped or crushed, as the pre-filled syringe may be broken even if you cannot see the break.
• Zdravila Idacio napolnjena injekcijska brizga ne uporabljajte, če vam je padlo iz rok ali je bila brizga strta, saj je lahko injekcijska brizga poškodovana, tudi če ne vidite razpok.
Efficacy of adalimumab for the treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and drug effects are substantially similar to that of adults at the same exposure levels.
Učinkovitost adalimumaba za zdravljenje mladostnikov s HS je napovedana na podlagi dokazane učinkovitosti in razmerja med izpostavljenostjo in odzivom pri odraslih bolnikih s HS ter verjetnosti, da so potek bolezni, patofiziologija in učinek zdravila bistveno podobni kot pri odraslih bolnikih pri enaki ravni izpostavljenosti.
People with more serious rheumatoid arthritis who have had the disease for a long time may have a higher than average risk of getting lymphoma and leukaemia (cancers that affect blood cells and bone marrow).
Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen že dolgo, obstaja povečana verjetnost, da zbolijo za limfomom in levkemijo (vrsto raka, ki prizadene krvne celice in kostni mozeg).
• In some patients the body may fail to produce enough of the blood cells that fight off infections or help you to stop bleeding.
• Pri nekaterih bolnikih telo ne ustvari dovolj krvnih celic, ki premagujejo okužbe ali pomagajo zaustaviti krvavitve.
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 6 below: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); and not known (cannot be estimated from the available data).
Naslednji seznam neželenih učinkov je osnovan na izkušnjah iz kliničnih preskušanj in iz obdobja trženja zdravila in jih razvršča po organskih sistemih in pogostnosti v preglednici 6, spodaj: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000) in neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) (<1/10.000).
A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Idacio cannot be excluded (see section 4.8).
Tveganja za razvoj hepatospleničnega limfoma celic T pri bolnikih, ki dobivajo zdravilo Idacio, ni mogoče izključiti (glejte poglavje 4.8).
In some rare cases, especially if you are taking other medicines that suppress the immune system, reactivation of HBV infection can be life-threatening.
V redkih primerih, zlasti če uporabljate druga zdravila, ki zavirajo imunski sistem, je reaktivacija HBV okužbe lahko smrtno nevarna.
4.2 Choose a different site (at least 2.5 centimeters away from the previous injection site) each time to reduce redness, irritation or other skin problems.
4.2 Vsakič izberite drugo mesto (ki je vsaj 2,5 centimetra oddaljeno od prejšnjega), da bi zmanjšali pordelost, draženje in druge težave s kožo.
During treatment with Idacio, other concomitant therapies (e.g. corticosteroids and/or immunomodulatory agents) should be optimised.
Med zdravljenjem z zdravilom Idacio je treba optimizirati druge sočasne terapije (npr. kortikosteroide in/ali imunomodulacijska zdravila).
Idacio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
Zdravilo Idacio se lahko uporablja kot monoterapija v primeru intolerance za metotreksat ali kadar nadaljnje zdravljenje z metotreksatom ni primerno.
Taking these results into consideration, Idacio is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2).
Z upoštevanjem teh ugotovitev je zdravilo Idacio priporočljivo uporabljati v kombinaciji z metotreksatom, kot monoterapijo pa pri bolnikih, za katere uporaba metotreksata ni primerna (glejte poglavje 4.2).
The decision to stop using Idacio should be discussed with your doctor.
O odločitvi, da bi prenehali uporabljati zdravilo Idacio, se morate posvetovati s svojim zdravnikom.
These results suggest that some patients who have not responded by week 4 benefit from continued maintenance therapy through week 12.
Ti rezultati nakazujejo, da nekaterim bolnikom, ki se ne odzovejo do 4. tedna, koristi nadaljevanje vzdrževalnega zdravljenja do 12 tedna.
Significant improvements at week 16 from baseline compared to placebo (Studies I and II) and MTX (study II) were demonstrated in the DLQI (Dermatology Life Quality Index).
Značilno izboljšanje od izhodišča do 16. tedna se je v primerjavi s placebom (študiji I in II) in metotreksatom (študija II) izkazalo v dermatološkem indeksu kakovosti življenja (DLQIDermatology Life Quality Index).
Note : images for illustration purposes only.
Opomba: slike so namenjene zgolj slikovni ponazoritvi
6.2 With a quick, short motion, push the needle into the skin at an angle of 45°.
6.2 S kratkim, hitrim gibom potisnite injekcijsko iglo v kožo pod kotom 45°.
• Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV infection or if you think you might be at risk of contracting HBV.
• Zdravniku morate povedati, če ste nosilec virusa hepatitisa B (HBV), če imate aktivno HBV okužbo ali če mislite, da bi se lahko nalezli HBV.
Warning: Do not use the pre-filled pen if the name on the label is not Idacio and/or the expiration date on the label has passed.
Opozorilo: Injekcijskega peresnika ne uporabljajte, če na injekcijskem peresniku ni imena Idacio in/ali če se je rok uporabnosti iztekel.
Patients who develop a new infection while undergoing treatment with Idacio, should be monitored closely and undergo a complete diagnostic evaluation.
Bolnike, pri katerih se med zdravljenjem z zdravilom Idacio pojavi nova okužba, je treba natančno nadzirati in opraviti morajo popolno diagnostično obravnavo.
If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis treatment before the initiation of Idacio, and in accordance with local recommendations.
Če ugotovite latentno tuberkulozo, morate pred uvedbo zdravila Idacio začeti z ustreznim protituberkuloznim profilaktičnim zdravljenjem v skladu z lokalnimi priporočili.
These infections have not consistently been recognised in patients taking TNFantagonists and this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.
Takšne okužbe se pri uporabnikih antagonistov TNF niso prepoznale vedno, zato je v primerih njihovega nastanka prihajalo do zamud pri ustreznem zdravljenju, kar je včasih povzročilo smrt.
1.5 Check your records for injection dates and injection sites to figure out the injection site for this session.
1.5 Preverite datume in mesta injiciranja, ki ste si jih zabeležili, da boste lahko določili mesto za naslednje injiciranje.
Patients treated with Idacio should be given the patient reminder card.
Bolniki, ki se zdravijo z zdravilom Idacio, morajo dobiti posebno opozorilno kartico za bolnike.
6.3 Gently push the white plunger rod all the way down until the syringe is empty.
6.3 Nežno potisnite bel bat do konca navzdol, dokler se injekcijska brizga ne izprazni.
Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralizing antibodies in rodents.
Z adalimumabom niso bile narejene niti raziskave kancerogenosti, niti standardne ocene plodnosti ter poporodne toksičnosti, in sicer zato, ker ni ustreznih modelov za protitelo z omejeno navzkrižno reaktivnostjo z glodalskim TNF, in zaradi nastanka nevtralizirajočih protiteles pri glodalcih.
Week 2 Week 12 Week 24 ***,** Statistically significant at p < 0.001, < 0.01 for all comparisons between adalimumab and placebo at weeks 2, 12 and 24 a Assessments in Ankylosing Spondylitis b Bath Ankylosing Spondylitis Disease Activity Index
24. teden ***,** Statistično značilno pri p < 0,001, < 0,01 za vse primerjave med adalimumabom in placebom po 2, 12 in 24 tednih a Ocene pri ankilozirajočem spondilitisu (Assessments in Ankylosing Spondylitis) b Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa (Bath Ankylosing Spondylitis Disease Activity Index)
Idacio should only be used during a pregnancy if needed.
Zdravilo Idacio se med nosečnostjo lahko uporablja samo, če je potrebno.
6.5 Center your thumb or forefinger on the textured finger pad and push the safety cover forward over the needle until you hear or feel it locks.
6.5 Palec položite na ustrezno reliefno mesto in potisnite varovalo naprej čez injekcijsko iglo, dokler ne slišite ali vidite, da je pravilno nameščeno.
Placebo/ MTXa Adalimumab/MTX
Placebo/MTXa Adalimumab Placebo/MTX
Table 21: Efficacy results at 12 weeks, HS Studies I and II
Preglednica 21: Rezultati učinkovitosti v 12. tednu, HS študiji I in II
Treatment with Idacio may result in the formation of autoimmune antibodies.
Zdravljenje z zdravilom Idacio lahko povzroči nastanek avtoimunskih protiteles.
Patients must therefore be monitored closely for infections, including tuberculosis, before, during and after treatment with Idacio.
Bolnike je zato treba pred, med in po zdravljenju z zdravilom Idacio natančno kontrolirati glede okužb, vključno s tuberkulozo.
Idacio can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment.
Zdravilo Idacio je mogoče uporabljati tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa brez predhodnega zdravljenja z metotreksatom.
If new areas of damaged skin appear during or after treatment or if existing marks or areas of damage change appearance, tell your doctor.
Če se vam med zdravljenjem ali po njem pojavijo nova poškodovana območja na koži, ali če se vam spremeni videz obstoječih oznak ali območij poškodb, morate to povedati zdravniku.
Symptoms of infections
Simptomi okužbe
Idacio is available in other presentations.
Zdravilo Idacio je na voljo v drugih oblikah.
Antibiotics may be continued during treatment with Idacio if necessary.
Med zdravljenjem z zdravilom Idacio lahko nadaljujete z antibiotičnim zdravljenjem, če je potrebno.
Idacio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1).
Zdravilo Idacio je mogoče uporabiti kot monoterapijo v primeru intolerance za metotreksat ali kadar nadaljnje zdravljenje z metotreksatom ni primerno (za učinkovitost monoterapije glejte poglavje 5.1).
You should continue to inject Idacio for as long as your doctor has told you.
Nadaljevati morate z injiciranjem zdravila Idacio tako dolgo, kot vam je naročil zdravnik.
Idacio is used to treat:
Zdravilo Idacio se uporablja za zdravljenje:
Table 17: efficacy results at 12 weeks, HS studies I and II
Preglednica 17: Rezultati učinkovitosti v 12. tednu, HS študiji I in II
Consequently, Idacio can be used during breast-feeding.
Posledično se zdravilo Idacio lahko uporablja med dojenjem.
Choose a different injection site (at least 2.5 centimeters away from the previous injection site) each time to reduce redness, irritation or other skin problems.
Vsakič izberite drugo mesto (ki je vsaj 2,5 centimetra oddaljeno od prejšnjega), da bi zmanjšali pordelost, draženje in druge težave s kožo.
• cancer, including cancer that affects the lymph system (lymphoma) and melanoma (a type of skin cancer);
• rak, vključno z rakom, ki zajame limfni sistem (limfom), in melanom (vrsta kožnega raka);
Patients should be tested for HBV infection before initiating treatment with Idacio.
Bolnike je treba pred začetkom zdravljenja z zdravilom Idacio testirati na okužbo s HBV.
b Among patients with baseline HS-related skin pain assessment ≥ 3, based on Numeric Rating Scale 0 - 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine.
b Med bolniki z izhodiščnim rezultatom 3 ali več pri ocenjevanju bolečine, povezane s hidradenitis suppurativa, po numerični ocenjevalni lestvici od 0 do 10; 0 = brez bolečin na koži, 10 = najhujša možna bolečina na koži.
Disease flare criteria were defined as a worsening of ≥ 30% from baseline in ≥ 3 of 6 Pediatric ACR core criteria, ≥ 2 active joints, and improvement of ≥ 30% in no more than 1 of the 6 criteria.
3 od 6 osnovnih meril »Pediatric ACR« za ≥ 30 % v primerjavi z izhodiščem, ≥ 2 aktivna sklepa in izboljšanje ne več kot 1 od 6 meril za ≥ 30 %.
It is recommended that, if possible, children be given all the scheduled vaccinations for their age before they start treatment with Idacio.
Če je mogoče, je za otroke priporočljivo, da pred začetkom zdravljenja z zdravilom Idacio opravijo vsa načrtovana cepljenja za njihovo starost.
Your doctor will decide if your child should receive Idacio.
On se bo odločil, ali lahko vaš otrok dobiva zdravilo Idacio.
Erosion score JSNd score amethotrexate b95% confidence intervals for the differences in change scores between methotrexate and adalimumab.
Ocena erozij Ocena ZSŠd ametotreksat b95 % intervali zaupanja za razlike v spremembi ocen med metotreksatom in adalimumabom cna podlagi analize rangov dzožitev sklepne špranje
8.1 To help you remember when and where to do your next injection, you should keep a record of the dates and injection sites used for your injections (Figure V).
8.1 Da si boste lažje zapomnili, kdaj in kje injicirati naslednji odmerek zdravila, si beležite datume in uporabljena mesta injiciranja (Slika V).
Axial spondyloarthritis without radiographic evidence of AS Idacio is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.
Aksialni spondiloartritis brez radiografskega dokaza za AS Zdravilo Idacio je indicirano za zdravljenje odraslih s hudim aksialnim spondiloartritisom brez radiografskega dokaza za AS, toda z objektivnimi znaki vnetja s povišanimi CRP in/ali MRI, ki so nezadostno reagirali na ali ne prenašajo nesteroidnih protivnetnih zdravil.
Idacio may have a minor influence on the ability to drive and use machines.
Zdravilo Idacio ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev.
• As cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will check your child for signs and symptoms of tuberculosis before starting Idacio.
• Ker so bili pri bolnikih, zdravljenih z adalimumabom, opisani primeri tuberkuloze, bo zdravnik vašega otroka pred začetkom zdravljenja z zdravilom Idacio preiskal glede znakov in simptomov tuberkuloze.
Idacio can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), corticosteroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).
Zdravilo Idacio se lahko uporablja skupaj z metotreksatom ali nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (sulfasalazinom, hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje), kortikosteroidi in zdravili proti bolečinam, vključno z nesteroidnimi protivnetnimi zdravili.
The following side effects have been observed with adalimumab:
Naslednji neželeni učinki so bili ugotovljeni med uporabo adalimumaba:
Idacio in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Zdravilo Idacio je v kombinaciji z metotreksatom indicirano za zdravljenje aktivnega poliartikularnega juvenilnega idiopatskega artritisa pri bolnikih od 2. leta starosti, ki se ne odzovejo ustrezno na eno ali več imunomodulirajočih antirevmatičnih zdravil (DMARDs - disease-modifying anti-rheumatic drugs).
8.1 To help you remember when and where to do your next injection, you should keep a record of the dates and injection sites used for your injections (Figure T).
8.1 Da si boste lažje zapomnili, kdaj in kje injicirati naslednji odmerek zdravila, si beležite datume in uporabljena mesta injiciranja (Slika T).
Aortic aneurysm, vascular arterial occlusion, thrombophlebitis
občasni aortna anevrizma, zapora arterijskega žilja, tromboflebitis
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 20.
Stopnja klinične remisije in kliničnega odziva (definiran kot zmanjšanje vrednosti PCDAI vsaj za 15 točk od začetne vrednosti) sta predstavljena v preglednici 20.
Your child should not take Idacio with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection.
Zdravila Idacio vaš otrok ne sme jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
• Tell your doctor if your child has a history of recurrent infections or other conditions that increase the risk of infections.
• Zdravniku povejte, če je vaš otrok imel v preteklosti ponavljajoče se okužbe ali druge bolezni, ki zvečujejo tveganje za okužbe.
Adalimumab treated patients had significantly greater improvement at week 12 which was maintained through week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).
Bolniki, ki so dobivali adalimumab, so imeli po 12 tednih značilno večje izboljšanje (ki se je ohranilo do 24. tedna) v obeh vprašalnikih, SF36 in ASQoL (Vprašalnik o kakovosti življenja pri ankilozirajočem spondilitisu - Ankylosing Spondylitis Quality of Life Questionnaire).
Idacio 40 mg/0.8 mL solution for injection for paediatric use may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days.
Idacio 40 mg/0,8 ml raztopine za injiciranje za pediatrično uporabo lahko shranjujete pri temperaturi do največ 25 ºC za obdobje 14 dni.
Among patients who were not in response at week 4, 43% of adalimumab maintenance patients responded by week 12 compared to 30% of placebo maintenance patients.
Med bolniki, ki se v 4. tednu niso odzvali, se je 43 % bolnikov na vzdrževalnem odmerku adalimumaba odzvalo do 12. tedna, v primerjavi s 30 % bolnikov na placebu.
After proper training in injection technique, patients may self-inject with Idacio if their physician determines that it is appropriate and with medical follow-up as necessary.
Bolniki, ki se naučijo pravilnega postopka injiciranja, si zdravilo Idacio lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
Idacio contains the active substance adalimumab, a medicine that acts on your body's immune (defence) system.
Zdravilo Idacio vsebuje učinkovino adalimumab, ki deluje na vaš imunski (obrambni) sistem .
The conduct and results of these tests should be recorded on your child's patient reminder card.
Izvedbo in rezultate teh preiskav je treba zabeležiti na otrokovi opozorilni kartici.
• As cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will check you for signs and symptoms of tuberculosis before starting Idacio.
• Ker so bili pri bolnikih, zdravljenih z adalimumabom, opisani primeri tuberkuloze, vas bo zdravnik pred začetkom zdravljenja z zdravilom Idacio preiskal glede znakov in simptomov tuberkuloze.
Week 36 a Patients with at least a partial response to adalimumab 40 mg weekly after 12 weeks of treatment.
36. teden a Bolniki z vsaj delnim odzivom na odmerek 40 mg adalimumaba po 12. tednih zdravljenja.
Table 17 Ps Study I (REVEAL) efficacy results at 16 weeks Placebo N=398 n (%)
Preglednica 17: Študija pri psoriazi I (REVEAL) Rezultati učinkovitosti po 16 tednih placebo n = 398 n (%)
• Idacio pre-filled syringe has a clear needle guard that covers the needle after the injection is complete.
• Zdravilo Idacio napolnjena injekcijska brizga ima prozorno varovalo, s katerim pokrijete injekcijsko iglo po končanem injiciranju.
• Do not give Idacio to children with polyarticular juvenile idiopathic arthritis below the age of 2
• Zdravila Idacio ne smete dati otroku s poliartikularnim juvenilnim idiopatskim artritisom, če je star manj kot 2 leti.
Idacio is used in adults to treat these conditions.
Zdravilo Idacio se uporablja pri odraslih za zdravljenje teh bolezni.
• Vaccinations: if possible children should be up to date with all vaccinations before using Idacio.
• Cepljenja: če je mogoče, naj vaš otrok pred začetkom uporabe zdravila Idacio opravi vsa potrebna cepljenja.
In a study of 64 patients with rheumatoid arthritis that were treated with adalimumab, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector T-, B -, NK-cells, monocyte/macrophages, and neutrophils.
V študiji 64 bolnikov z revmatoidnim artritisom, zdravljenih z adalimumabom, niso odkrili znakov zavrtja odložene preobčutljivosti, znižanja koncentracije imunoglobulinov ali spremembe števila efektorskih celic T in B, naravnih celic ubijalk, monocitov/makrofagov ali nevtrofilcev.